SLC22A8

Organic anion transporter 3 · Q8TCC7 · SLC22A8 on Sugi Atlas →

118,893 patent compounds predicted against SLC22A8, 93,738 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Cefatrizine (SCHEMBL49503)	0.61	3/20
Cefotiam (SCHEMBL65480)	0.51	3/20
Cephalothin (SCHEMBL2990)	1.00	2/20
Cephaloridine (SCHEMBL3936)	1.00	2/20
Cefotaxime (SCHEMBL15410)	1.00	2/20
Cefotaxime (SCHEMBL15411)	1.00	2/20
Ceftriaxone (SCHEMBL23355)	1.00	2/20
Ceftriaxone (SCHEMBL23356)	1.00	2/20
Cefoperazone (SCHEMBL37056)	1.00	2/20
Cefamandole (SCHEMBL37287)	1.00	2/20
Cefoperazone (SCHEMBL40452)	0.99	2/20
Ceftriaxone (SCHEMBL40850)	0.99	2/20
Cefotaxime (SCHEMBL41091)	0.98	2/20
Cefotaxime (SCHEMBL41093)	0.98	2/20
Cefpodoxime (SCHEMBL27072)	0.87	2/20
Cefpodoxime (SCHEMBL69122)	0.87	2/20
Ceftriaxone (SCHEMBL23354)	0.80	2/20
Ceftriaxone (SCHEMBL40849)	0.79	2/20
Cefonicid (SCHEMBL60350)	0.77	2/20
Cefonicid (SCHEMBL41894)	0.76	2/20

Clinical trials — most relevant to SLC22A8 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Genetic Basis for Variation in the Renal Elimination of Metformin	PHASE4	COMPLETED
Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use	PHASE4	COMPLETED
Organic Cation Transporter 1 (OCT1), on Response to Metformin in Healthy Subjects	PHASE4	COMPLETED
Effect of Age on the Renal Clearance of Adefovir	PHASE4	WITHDRAWN
A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis	PHASE2	UNKNOWN
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)	PHASE2	COMPLETED
Open Label Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1	PHASE1	COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime	PHASE1	COMPLETED
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias	PHASE1	COMPLETED
Genetic Variation in Organic Cation Transport 1 (OCT1) and Its Significance for Morphine Pharmacokinetics	PHASE1	COMPLETED
Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)	PHASE1	COMPLETED
Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study	PHASE1	COMPLETED
Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects	PHASE1	COMPLETED
A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects	PHASE1	COMPLETED
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer	EARLY_PHASE1	UNKNOWN
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters	EARLY_PHASE1	COMPLETED
Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I	EARLY_PHASE1	COMPLETED
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs	nan	COMPLETED
Cancer and Hearing Loss Related in Children	nan	COMPLETED
Genetics of Hyperuricemia Therapy in Hmong	nan	COMPLETED
Influence of OCTN2 Variants on Carnitine Status and Plasma Triglycerides	nan	COMPLETED
PET/CT Scans Using the Tracer 11C-Csar, a Bile Acid Analog, to Depict and Visualize Cholestatic Disorders in Patients with Genetic Liver Disorders and Healthy Individuals	nan	ENROLLING_BY_INVITATION
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy	nan	COMPLETED
SLC13A5 Deficiency Natural History Study - Remote Only	nan	ENROLLING_BY_INVITATION
Oxalate and Citrate in Humans - Response to Citrate	nan	RECRUITING
ADPKD Alterations in Hepatic Transporter Function	nan	COMPLETED
Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL	nan	COMPLETED
Impact of Genetics on Metformin Pharmacokinetics	nan	COMPLETED
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors	nan	WITHDRAWN
The Furosemide Stress Test, Electrolytes Response and Renal Index in Critically Ill Patients	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC22A8 binder may also engage these)

Protein	Name	Similarity
Q4W8A2	—	1.000	Q4W8A2 →
Q5R9C4	—	1.000	Q5R9C4 →
O88909	—	1.000	O88909 →
Q8HY24	—	0.999	Q8HY24 →
A6NK97	—	0.998	A6NK97 →
Q70BM6	—	0.997	Q70BM6 →
O35956	—	0.993	O35956 →
Q9R1U7	—	0.992	Q9R1U7 →
Q80UJ1	—	0.988	Q80UJ1 →
Q9Y226	—	0.988	Q9Y226 →
Q864Z3	—	0.987	Q864Z3 →
Q8VC69	—	0.987	Q8VC69 →
Q6NYN7	—	0.987	Q6NYN7 →
Q5RLM2	—	0.986	Q5RLM2 →
O57379	—	0.986	O57379 →
Q91WU2	—	0.985	Q91WU2 →
Q6A4L0	—	0.985	Q6A4L0 →
Q5RCH6	—	0.984	Q5RCH6 →
Q66J52	—	0.984	Q66J52 →
Q9TSY7	—	0.983	Q9TSY7 →
B2GV36	—	0.980	B2GV36 →
Q5R540	—	0.979	Q5R540 →
Q6NUB3	—	0.979	Q6NUB3 →
A7MBE0	—	0.977	A7MBE0 →
Q9Y694	—	0.977	Q9Y694 →
SLC22A1	Solute carrier family 22 member 1	0.977	landscape →
Q863T6	—	0.975	Q863T6 →
SLC22A6	Solute carrier family 22 member 6	0.975	landscape →
Q8MK48	—	0.975	Q8MK48 →
O08966	—	0.973	O08966 →